318 related articles for article (PubMed ID: 23882450)
1. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Hinson AR; Jones R; Crose LE; Belyea BC; Barr FG; Linardic CM
Front Oncol; 2013; 3():183. PubMed ID: 23882450
[TBL] [Abstract][Full Text] [Related]
2. Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.
Jacob AG; O'Brien D; Singh RK; Comiskey DF; Littleton RM; Mohammad F; Gladman JT; Widmann MC; Jeyaraj SC; Bolinger C; Anderson JR; Barkauskas DA; Boris-Lawrie K; Chandler DS
Neoplasia; 2013 Sep; 15(9):1049-63. PubMed ID: 24027430
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
[TBL] [Abstract][Full Text] [Related]
4. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
5. Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Millino C; Pacchioni B; Celegato B; Bisogno G; Romualdi C; Rosolen A; Lanfranchi G
BMC Cancer; 2016 Nov; 16(1):886. PubMed ID: 27842508
[TBL] [Abstract][Full Text] [Related]
6. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
Harel M; Ferrer FA; Shapiro LH; Makari JH
Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
8. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study.
Kodet R; Newton WA; Hamoudi AB; Asmar L; Jacobs DL; Maurer HM
Am J Surg Pathol; 1993 May; 17(5):443-53. PubMed ID: 8470759
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
11. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice.
Seitz G; Pfeiffer M; Fuchs J; Warmann SW; Leuschner I; Vokuhl C; Lang P; Handgretinger R; Armeanu-Ebinger S
Oncol Rep; 2010 Oct; 24(4):1067-72. PubMed ID: 20811690
[TBL] [Abstract][Full Text] [Related]
13. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
14. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
[TBL] [Abstract][Full Text] [Related]
18. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
[TBL] [Abstract][Full Text] [Related]
19. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.
Libura J; Drukala J; Majka M; Tomescu O; Navenot JM; Kucia M; Marquez L; Peiper SC; Barr FG; Janowska-Wieczorek A; Ratajczak MZ
Blood; 2002 Oct; 100(7):2597-606. PubMed ID: 12239174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]